GO:0005520 insulin-like growth factor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005520 (insulin-like growth factor binding) is a molecular function describing the selective binding of a protein to insulin-like growth factors (IGFs), a family of insulin-homologous polypeptides that are immunologically distinct from insulin.
• The function is executed mainly by IGFBPs (IGFBP-1 to IGFBP-7) and by IGF2BP family RNA-binding proteins, which together control IGF ligand availability, half-life and downstream signaling.
• IGF binding proteins are clinically relevant biomarkers: IGFBP-1 tracks insulin resistance and cardiovascular risk, while IGFBP-7 is a marker of diabetic kidney disease and of aged tissue.
• IGF2-driven fibroblast activation and IGF2BP1-mediated RNA stabilization promote tumor immune evasion and resistance to immunotherapy, making this function a therapeutic target.
• CRISPR knockout, point-mutation, knock-in and overexpression models allow causal dissection of IGF binding protein function in cancer, metabolic and renal disease.
• Studying GO:0005520 requires ligand-binding assays, transcriptomics, proteomics and functional CRISPR screens to link binding events to phenotype.
Description
GO:0005520, insulin-like growth factor binding, is a molecular function in the Gene Ontology that describes the selective, non-covalent interaction of a protein with an insulin-like growth factor (IGF). IGFs are polypeptides structurally homologous to insulin that share many of insulin's biological activities but are immunologically distinct from it, and their bioavailability is controlled by binding proteins rather than by storage in secretory granules. Because IGF signaling drives proliferation, survival, migration and metabolism, the proteins that bind IGFs act as rheostats that tune local and systemic IGF action. Researchers study GO:0005520 to understand how IGF sequestration, transport and release shape development, tissue repair, metabolic homeostasis and disease progression. The function is also central to cancer biology, where IGF2 and IGF2BP proteins sustain autocrine and paracrine growth loops and contribute to immune escape. In this article we integrate the QuickGO definition with verified PubMed literature to describe the mechanism, key genes, disease links and experimental methods used to interrogate insulin-like growth factor binding.
insulin-like growth factor binding At A Glance
| GO ID | GO:0005520 |
|---|---|
| GO term | insulin-like growth factor binding |
| Ontology | molecular_function |
| Synonym | IGF binding |
| Definition | Binding to an insulin-like growth factor, any member of a group of polypeptides that are structurally homologous to insulin and share many of its biological activities, but are immunologically distinct from it. |
| Major function | Selective capture, transport, sequestration or post-transcriptional regulation of IGF ligands and IGF-related transcripts. |
| Representative proteins | IGFBP-1, IGFBP-7, IGF2BP1 and related IGFBP/IGF2BP family members. |
| Disease relevance | Cardiovascular disease, polycystic ovary syndrome, diabetic kidney disease, cancer and immunotherapy resistance. |
| Research methods | Ligand-binding assays, single-cell RNA sequencing, CRISPR screens, transcriptomics and proteomics. |
What Is GO:0005520?
In the Gene Ontology, GO:0005520 (insulin-like growth factor binding) is defined as binding to an insulin-like growth factor, any member of a group of polypeptides that are structurally homologous to insulin and share many of its biological activities, but are immunologically distinct from it. The synonym IGF binding is used interchangeably. This is a molecular_function term: it describes the binding event itself, not the downstream signaling cascade or the cellular location. Proteins annotated with GO:0005520 include secreted IGF-binding proteins (IGFBPs) that sequester IGF ligands in the extracellular space and IGF2 mRNA-binding proteins (IGF2BPs) that bind IGF2 transcripts and regulate their fate. The term is therefore a node that connects ligand availability, transport and post-transcriptional control of IGF-related genes.
Why Is insulin-like growth factor binding Important in Cell Biology?
Insulin-like growth factor binding is important because it determines how much free, bioactive IGF is available to activate the IGF1 receptor and downstream PI3K-AKT and MAPK pathways, thereby influencing cell growth, survival, metabolism and immune interactions. Dysregulated IGF binding is linked to cardiovascular risk, insulin resistance, polycystic ovary syndrome, progressive diabetic kidney disease and cancer immunotherapy resistance, so the function is both a biomarker source and a therapeutic target. Because the function is mediated by secreted proteins and RNA-binding proteins, it can be manipulated with CRISPR-based models to establish causality between binding events and disease phenotypes.
• Controls IGF ligand bioavailability and half-life, thereby tuning IGF1R signaling strength and duration.
• Provides clinically used biomarkers such as IGFBP-1 for cardiovascular and metabolic risk assessment.
• Links insulin resistance and hyperinsulinemia to reduced IGFBP-1 levels in polycystic ovary syndrome.
• IGFBP-7 is a critical promoter of progressive diabetic kidney disease and a marker of aged dental pulp.
• IGF2 produced by fibroblasts drives tumor immunoevasion and resistance to immunotherapy.
• IGF2BP1 stabilizes oncogenic transcripts and is a therapeutic target in hematological and solid cancers.
• IGF mimetic materials exploit IGF binding principles for regenerative and metabolic applications.
• The function is amenable to CRISPR knockout, point-mutation, knock-in and overexpression modeling.
• Single-cell RNA sequencing has identified IGFBP-7 in specific aged tissue compartments.
• Targeting IGF2BP proteins is an active medicinal chemistry strategy for cancer treatment.
Molecular Mechanism of insulin-like growth factor binding
Ligand recognition and high-affinity capture
In simple terms: Binding proteins grab IGF molecules so they cannot immediately activate receptors.
The core event of GO:0005520 is high-affinity, non-covalent recognition of an IGF ligand by a binding protein. IGFBP family members contain conserved cysteine-rich N- and C-terminal domains that form a compact IGF-binding pocket, allowing them to sequester IGF1 and IGF2 in extracellular fluids. This capture prevents IGF from engaging the IGF1 receptor and extends the ligand's circulating half-life, effectively converting a short-lived hormone into a buffered reservoir. The specificity of this interaction is what distinguishes IGF binding from insulin binding, since IGFs are immunologically distinct from insulin despite structural homology.
Post-transcriptional IGF2 mRNA recognition by IGF2BPs
In simple terms: A second class of proteins binds IGF2 RNA rather than the IGF2 protein.
IGF2BP1 and related IGF2BP family proteins bind IGF2 mRNA and other transcripts through KH domains, regulating their stability, localization and translation. This RNA-centric mode of IGF binding links GO:0005520 to post-transcriptional gene regulation and explains why IGF2BP1 is annotated with IGF-related binding activity. In hematological malignancies, IGF2BP1 sustains oncogenic transcript networks, and pharmacological targeting of IGF2BPs is being pursued as an anti-cancer strategy.
Modulation of IGF signaling output
In simple terms: Whether IGFs are free or bound decides how strong the growth signal is.
Bound IGF is largely inactive until proteases or binding-protein modifications release the ligand, so the balance between free and bound IGF sets the amplitude of IGF1R signaling. In tumors, fibroblast-derived IGF2 can act in a paracrine manner to promote immunoevasion and resistance to immunotherapy, illustrating how ligand availability translates into immune phenotype. Thus, GO:0005520 is not a passive storage function but an active determinant of signaling output.
Tissue-specific and context-dependent regulation
In simple terms: Different tissues use different binding proteins to fine-tune IGF action.
Single-cell RNA sequencing of aged dental pulp identified IGFBP-7 in specific cell populations, showing that IGF binding proteins are expressed in a cell-type-restricted manner. In the kidney, IGFBP-7 acts as a critical promoter of progressive diabetic kidney disease, indicating that local IGF binding can drive organ pathology. IGFBP-1 levels are inversely related to insulin and are altered in polycystic ovary syndrome, providing a systemic example of metabolic regulation of IGF binding.
Therapeutic and engineering implications
In simple terms: Because binding controls IGF activity, it can be engineered for therapy.
The development of IGF mimetic materials shows that the principles of IGF binding can be harnessed to design biologics or biomaterials with tailored activity. Targeting IGF2BPs with small molecules is an emerging cancer strategy, and blocking IGF2-mediated fibroblast crosstalk may overcome immunotherapy resistance. These efforts depend on precise knowledge of which binding protein engages which ligand in a given disease context.
Key Genes Involved in GO:0005520 insulin-like growth factor binding
The following genes and proteins are central to insulin-like growth factor binding (GO:0005520) and are frequently studied in cancer, metabolic and renal disease research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IGFBP1 | Secreted IGF-binding protein that modulates free IGF availability | Biomarker of cardiovascular disease and insulin resistance; altered in PCOS |
| IGFBP7 | Secreted IGF-binding protein with tissue-specific expression | Marker of aged dental pulp and promoter of diabetic kidney disease |
| IGF2BP1 | RNA-binding protein that binds IGF2 mRNA and other transcripts | Oncogenic driver in hematological diseases and cancer target |
| IGF2BP2 | IGF2 mRNA-binding protein family member | Implicated in metabolic and cancer biology through IGF2 transcript regulation |
| IGF2BP3 | IGF2 mRNA-binding protein family member | Studied as an oncofetal RNA-binding protein in cancer |
| IGF2 | IGF ligand produced by fibroblasts and tumor cells | Drives immunoevasion and immunotherapy resistance |
| IGF1 | IGF ligand structurally homologous to insulin | Classic ligand for IGF binding proteins and IGF1R signaling |
| IGF1R | Receptor tyrosine kinase activated by free IGF | Downstream effector of IGF binding balance |
| IGFBP2 | Secreted IGF-binding protein | Modulates IGF action in multiple tissues |
| IGFBP3 | Major circulating IGF carrier protein | Controls IGF half-life and bioavailability |
| IGFBP4 | Secreted IGF-binding protein | Regulates local IGF signaling |
| IGFBP5 | Secreted IGF-binding protein | Implicated in tissue remodeling and cancer |
| IGFBP6 | Secreted IGF-binding protein | Modulates IGF activity in extracellular matrix |
| INS | Insulin, the structural homolog of IGFs | Provides evolutionary context for IGF binding specificity |
| IGF2BP1 paralogs | RNA-binding proteins with overlapping IGF2 mRNA targets | Potential redundancy in post-transcriptional IGF regulation |
| IGFBP7 receptor partners | Proteins that mediate IGFBP-7 downstream effects | Relevant to kidney and aging research |
How Is insulin-like growth factor binding Regulated?
Insulin-like growth factor binding is regulated at multiple levels. Systemically, insulin suppresses IGFBP-1 production, so IGFBP-1 levels are inversely related to insulin and serve as a marker of insulin resistance in polycystic ovary syndrome. In cardiovascular disease, IGFBP-1 is studied as a biomarker whose circulating levels reflect metabolic and vascular risk. Locally, IGFBP-7 expression is cell-type restricted and changes with aging and kidney disease, as shown by single-cell RNA sequencing and functional studies. At the post-transcriptional level, IGF2BP proteins control the stability and translation of IGF2 mRNA, adding an RNA-centric layer of regulation to GO:0005520. Finally, tumor microenvironment fibroblasts can produce IGF2 that acts on neighboring cells, linking stromal signaling to IGF binding and immune escape.
insulin-like growth factor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IGF2 | Tumor immunoevasion and immunotherapy resistance | Knockout of IGF2 in fibroblast co-culture with tumor cells |
| IGFBP1 | Cardiovascular disease and insulin resistance | Overexpression and knockout in hepatocyte models |
| IGFBP7 | Diabetic kidney disease and tissue aging | Kidney organoid or podocyte knockout models |
| IGF2BP1 | Hematological malignancies and solid tumors | CRISPR knockout in leukemia cell lines |
| IGF2BP2/3 | Cancer and metabolic disease | Point-mutation knock-in of KH domain variants |
Cancer and immunotherapy resistance
IGF2 produced by fibroblasts drives tumor immunoevasion and confers resistance to immunotherapy, establishing IGF ligand availability as a determinant of immune checkpoint blockade efficacy. IGF2BP1 and related RNA-binding proteins sustain oncogenic transcript programs in hematological malignancies and solid tumors, and targeting IGF2BPs is being explored as an anti-cancer strategy. These findings position GO:0005520 as a node connecting IGF binding to tumor immune escape and therapeutic resistance.
Cardiometabolic and endocrine disease
IGFBP-1 is a biomarker of cardiovascular disease and is inversely associated with insulin, making it relevant to insulin resistance and metabolic syndrome. In polycystic ovary syndrome, a systematic review and meta-analysis found that IGFBP-1 and insulin levels are altered, supporting a role for IGF binding in endocrine dysfunction. These studies show that systemic IGF binding proteins integrate metabolic signals with cardiovascular and reproductive risk.
Diabetic kidney disease and tissue aging
Renal IGFBP-7 is a critical promoter of progressive diabetic kidney disease, indicating that local IGF binding can directly drive organ pathology. Single-cell RNA sequencing of aged dental pulp identified IGFBP-7 as a marker of aging in specific cell populations, suggesting that IGF binding proteins participate in tissue aging across organs. Together, these findings link GO:0005520 to chronic kidney disease and age-related tissue changes.
Therapeutic engineering and IGF mimetics
The development of IGF mimetic materials demonstrates that the molecular principles of IGF binding can be repurposed for therapeutic and regenerative applications. Such engineered molecules must respect the specificity of IGF binding proteins to avoid off-target activation of insulin or IGF1 receptors. This translational angle reinforces the importance of understanding GO:0005520 at structural and functional resolution.
From insulin-like growth factor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of IGFBP-1 alter free IGF and metabolic phenotype? | CRISPR knockout in hepatocytes or mouse liver |
| Does IGF2 from fibroblasts drive immunotherapy resistance? | IGF2 knockout fibroblasts co-cultured with tumor cells |
| Is IGFBP-7 required for diabetic kidney disease progression? | Kidney-specific knockout or knockdown in disease models |
| How does IGF2BP1 recognize IGF2 mRNA? | Point-mutation knock-in of RNA-binding domain residues |
| Can IGFBP-7 be used as an aging marker? | Tagged knock-in reporter in dental pulp or kidney cells |
| Does overexpression of IGFBP-1 protect against cardiovascular risk? | Overexpression in metabolic cell models |
How to Study the insulin-like growth factor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Binding affinity and kinetics for IGF ligands | Characterizing IGFBP-IGF interactions |
| ELISA | Circulating IGFBP-1 or IGFBP-7 protein levels | Biomarker studies in cardiovascular and kidney disease |
| Single-cell RNA sequencing | Cell-type-specific expression of IGFBP genes | Aging and tissue atlas studies |
| CRISPR knockout screening | Requirement of IGF binding genes for phenotype | Cancer and metabolic disease models |
| RNA immunoprecipitation | IGF2 mRNA binding by IGF2BP proteins | Post-transcriptional regulation studies |
| Western blot | Protein expression and knockdown efficiency | Validation of CRISPR and overexpression models |
| Mass spectrometry | Proteomic identification of IGFBP complexes | Interaction network discovery |
| Meta-analysis of clinical cohorts | Association of IGFBP levels with disease | PCOS and cardiovascular risk assessment |
Ligand-binding and biochemical assays
Direct binding assays such as radioligand binding, surface plasmon resonance and ELISA-based competition are used to measure the affinity and specificity of IGF binding proteins for IGF1 and IGF2. These methods establish whether a candidate protein truly executes GO:0005520 and quantify how mutations affect binding.
Single-cell and bulk transcriptomics
Single-cell RNA sequencing identified IGFBP-7 in aged dental pulp, demonstrating how transcriptomics can reveal cell-type-specific expression of IGF binding proteins. Bulk RNA sequencing and meta-analysis are used to compare IGFBP-1 and insulin levels across patient cohorts in polycystic ovary syndrome and cardiovascular disease.
Functional CRISPR screens
CRISPR knockout and interference screens can test whether IGF binding protein genes are required for tumor immune evasion, kidney disease progression or metabolic phenotypes. Such screens link loss of GO:0005520 activity to measurable cellular outcomes.
Proteomics and biomarker quantification
Mass spectrometry and immunoassays quantify circulating IGFBP levels as biomarkers of cardiovascular and metabolic disease. Proteomic profiling of tumor and stromal compartments can identify IGF2 and IGFBP proteins that mediate paracrine signaling and immunotherapy resistance.
How CRISPR Can Be Used to Study GO:0005520 insulin-like growth factor binding
Knockout
CRISPR knockout of IGFBP or IGF2BP genes is used to test whether loss of IGF binding activity alters free IGF levels, downstream signaling and disease phenotypes. For example, knocking out IGF2 in fibroblasts can reverse tumor immunoevasion in co-culture systems, and knocking out IGFBP-7 can test its requirement in diabetic kidney disease models.
Point Mutation
Point-mutation knock-in can disrupt specific residues in the IGF-binding pocket or in IGF2BP KH domains to separate ligand binding from other functions. Such models are valuable for determining which amino acids are essential for GO:0005520 activity without deleting the entire protein.
Knock-in
Tagged knock-in of endogenous IGFBP or IGF2BP loci enables imaging, immunoprecipitation and proximity labeling of IGF binding complexes in their native context. This approach is particularly useful for tracking cell-type-specific expression of IGFBP-7 in aging and kidney tissue.
Overexpression
Overexpression of IGFBP-1 or other binding proteins can test whether increased IGF sequestration protects against metabolic or cardiovascular phenotypes. Conversely, overexpression of IGF2 or IGF2BP1 can model tumor-promoting states and immunotherapy resistance.
How EDITGENE Supports insulin-like growth factor binding Research
Researchers studying insulin-like growth factor binding-related genes often need to determine whether a candidate gene is causally involved in ligand sequestration, signaling output or disease progression, and CRISPR-based models provide the most direct way to establish that causality. EDITGENE supports this work with validated knockout, point-mutation, knock-in, overexpression and library screening services tailored to IGF binding biology.
Contact EDITGENE today to design your custom CRISPR model for insulin-like growth factor binding research.
Frequently Asked Questions About insulin-like growth factor binding
What is GO:0005520 insulin-like growth factor binding?
GO:0005520 is a Gene Ontology molecular function defined as binding to an insulin-like growth factor, a polypeptide structurally homologous to insulin but immunologically distinct from it.
What genes are involved in insulin-like growth factor binding?
Key genes include IGFBP1, IGFBP7, IGF2BP1, IGF2BP2, IGF2BP3, IGF1, IGF2 and IGF1R, which together control IGF ligand availability and signaling.
Why is IGFBP-1 important in cardiovascular disease?
IGFBP-1 is studied as a biomarker of cardiovascular disease and is inversely related to insulin, linking IGF binding to metabolic and vascular risk.
How is IGFBP-7 linked to kidney disease?
Renal IGFBP-7 is a critical promoter of progressive diabetic kidney disease, and its expression is cell-type restricted in kidney tissue.
What role does IGF2 play in immunotherapy resistance?
Fibroblast-derived IGF2 drives tumor immunoevasion and confers resistance to immunotherapy, making IGF2 binding a therapeutic target.
What are IGF2BP proteins?
IGF2BP1, IGF2BP2 and IGF2BP3 are RNA-binding proteins that bind IGF2 mRNA and other transcripts, regulating their stability and translation in cancer and hematological diseases.
How can CRISPR be used to study insulin-like growth factor binding?
CRISPR knockout, point-mutation, knock-in and overexpression models can test whether IGF binding proteins are causally required for disease phenotypes.
Is IGFBP-7 a marker of aging?
Single-cell RNA sequencing identified IGFBP-7 in aged dental pulp, suggesting it marks age-related changes in specific cell populations.
What methods measure IGF binding activity?
Surface plasmon resonance, ELISA, RNA immunoprecipitation, single-cell RNA sequencing and CRISPR screens are commonly used to measure IGF binding and its consequences.
Can IGF binding be targeted therapeutically?
Yes, targeting IGF2BPs with small molecules and blocking IGF2-mediated fibroblast crosstalk are active strategies, and IGF mimetic materials exploit IGF binding principles.
Conclusion
GO:0005520 insulin-like growth factor binding is a compact molecular function with broad biological reach, controlling IGF ligand availability, post-transcriptional IGF2 regulation and downstream signaling in health and disease. Its clinical importance spans cardiovascular disease, polycystic ovary syndrome, diabetic kidney disease, tissue aging and cancer immunotherapy resistance. CRISPR-based knockout, point-mutation, knock-in and overexpression models, combined with transcriptomics, proteomics and binding assays, provide the tools needed to move from correlation to causality in IGF binding research.
References
- 1. Song D et al.. 2024. Insulin-like growth factor 2 drives fibroblast-mediated tumor immunoevasion and confers resistance to immunotherapy.. J Clin Invest 134(22) PMID: 39545420
- 2. Lewitt MS et al.. 2024. Insulin-like Growth Factor-Binding Protein-1 (IGFBP-1) as a Biomarker of Cardiovascular Disease.. Biomolecules 14(11) PMID: 39595651
- 3. Tong Z et al.. 2025. Insulin-like growth factor binding protein 7 identified in aged dental pulp by single-cell RNA sequencing.. J Adv Res 76:371-385 PMID: 39674503
- 4. Yu JT et al.. 2025. Renal insulin-like growth factor binding-protein 7 is a critical promoter of progressive diabetic kidney disease.. Nat Commun 17(1):30 PMID: 41326394
- 5. Ma S et al.. 2024. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in hematological diseases.. Mol Med 30(1):165 PMID: 39342091
- 6. Jin Y et al.. 2023. Insulin-like growth factor binding protein-1 and insulin in polycystic ovary syndrome: a systematic review and meta-analysis.. Front Endocrinol (Lausanne) 14:1279717 PMID: 38174331
- 7. Cai Y et al.. 2024. Targeting insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) for the treatment of cancer.. Eur J Med Chem 268:116241 PMID: 38382391
- 8. Roy A et al.. 2025. Development of Insulin-Like Growth Factor Mimetic Materials.. Adv Biol (Weinh) 9(11):e00327 PMID: 40904194
